Latest filingSep 02, 2026Most recent Form 4
INKT
MiNK Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$00 sells
Net open-market+$05 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period5transactions
- A · Grants / awards · dominant5 · 100%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- Director · dominant5 · 100%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCorvese BrianCommon Stock · Direct
54,770Sep 01, 2026
Ryan BarbaraCommon Stock · Direct
23,591Sep 01, 2026
Behner PeterCommon Stock · Direct
24,404Sep 01, 2026
Holcomb John BradleyCommon Stock · Direct
4,691Sep 01, 2026
Wiinberg UlfCommon Stock · Direct
23,929Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- CB+$17.9k
- RB+$17.8k
- BP+$16.3k
- WU+$14.0k
- HB+$13.5k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
INKT transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| INKT | WIINBERG ULF | DIR | grant | 1.27k | $1.40M | A | 0.0% | 09/02 | 09/01 | |
| INKT | Holcomb John Bradley | DIR | grant | 1.23k | $1.35M | A | 0.0% | 09/02 | 09/01 | |
| INKT | Behner Peter | DIR | grant | 1.48k | $1.62M | A | 0.0% | 09/02 | 09/01 | |
| INKT | Ryan Barbara | DIR | grant | 1.62k | $1.77M | A | 0.0% | 09/02 | 09/01 | |
| INKT | Corvese Brian | DIR | grant | 1.63k | $1.78M | A | 0.0% | 09/02 | 09/01 |
MiNK Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at MiNK Therapeutics, Inc.?
WIINBERG ULF, Holcomb John Bradley, Behner Peter, Ryan Barbara, Corvese Brian.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.